Sector-wide catalysts, such as favorable regulatory approvals, have lifted pdyn stock price in recent sessions. Investors with a long-term horizon might see this as part of a broader bullish phase for small- to mid-cap biotech firms. In this article, we will dive into their performance and evaluate whether these stocks are poised to become the next big winners for your portfolio. Volatility often hides opportunity, and many of these software stocks are now oversold and can rebound when sentiment shifts. As such, it’s worth looking into the stocks that have plunged the most.